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increased antigen loading at the cell sur-
face, less than 10% of the CD1b mole-
cules would be protonated at position
60. With a similar percentage protonated
at position 62, very few CD1b molecules
would have both anionic tethers neutral-
ized. However, because the surrounding
amino acids in a folded protein can sub-
stantially influence ionization, the authors
asserted that estimates based on the
pKa of free amino acids are not accurate.
In fact, a predictive model that takes pro-
tein context into account suggested that
more than a few percent of the CD1b mol-
ecules would be protonated at the pH of
late endosomes and lysosomes.
Although the results provided by Relloso
et al. (2008) give great insight into the dy-
namics of CD1b lipid antigen loading, an
unresolved issue is how the functions of
the sphingolipid activator proteins in lyso-
somes, such as the saposins, interplay
with the direct effects of pH on CD1b con-
formation. For example, do these acces-
sory proteins interact preferentially with
the protonated form of CD1b, or do they
stabilize the more open conformation?
Also, do anionic switches influence the be-
havior of the other CD1 isoforms? Further
studies clearly are needed to determine if
the current findings can be generalized to
lipid loading of other CD1 isoforms.
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In this issue of Immunity, Chaturvedi et al. (2008) describe a mechanism for the bridging of innate and
adaptive immune receptor functions. In their model, B cell-receptor signaling induces the fusion of Toll-like
receptor 9 (TLR9)-containing endosomes with internalized signaling-competent BCR into autophagosomes.Pattern-recognition receptors (PRRs) act
as sentinels of the immune system, alert-
ing both the innate and the adaptive im-
mune system to the presence of microbial
pathogens (Medzhitov, 2007). Invariant
regions within microbes, such as cell-
wall components of bacteria and fungi,
trigger signaling through PRR and induce
immune activation. Toll-like receptors
(TLRs) are a well-characterized subset of
PRR and play a key role in the detection
of microbes, as in the case of TLR4
triggering by lipopolysaccharide (LPS),
a Gram-negative bacterial-cell-wall com-
ponent. Perhaps one of the more intrigu-
ing problems inherent to TLR specificityis their ability to differentiate viral- from
self-antigens, because viruses share al-
most all of their constitutive parts with
host cells and exploit host cell machinery
in order to replicate. How TLR7 and TLR9,
which detect single-stranded RNA and
unmethylated DNA, respectively, respond
only to foreign nucleic acids remains
incompletely understood.
The influence of TLR signaling on the
adaptive immune response has been the
subject of intense study over the past
several years. B cells express germ-line-
encoded TLRs, including both TLR7 and
TLR9, as well as B cell receptors (BCR),
which are highly diversified through so-Immmatic hypermutation of the V(D)J region.
BCR ligation results in activation of MAP-
kinase-signaling cascades, receptor-anti-
gen internalization, and the induction of
antigen processing for presentation on
MHC class II molecules. Signals induced
via TLR9 ligation in B cells independently
activate downstream signals through
MAP kinases and result in nuclear factor-
kappa B (NF-kB) activation and the initia-
tion of proliferation and upregulation of
activation markers. The induction of sig-
naling via TLR9 litigation in B cells is not
dependent on BCR ligation, but coligation
of the two receptors induces increased
activation of NF-kB and phosphorylationunity 28, June 2008 ª2008 Elsevier Inc. 729
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PreviewsFigure 1. Strategies for the Enhancement of BCR-Initiated B Cell Activation
Pathogens engaged by BCR generate signals as a consequence of BCR aggregation. If a microbe is bound by complement proteins generated via the alternative
pathway of complement activation (left), these proteins can then engage and recruit the CD19 and CD21 coreceptors, which generate signals through CD19 and
other associated components of the complex to enhance signals for activation. Alternatively, TLR4 recognition of bacterial cell-wall LPS on the surface of Gram-
negative bacteria increases signaling through the BCR (middle) by providing synergy for the rapid triggering of B cell activation and differentiation pathways and
by relaxing requirements for CD4+ T cell help. Fusion of TLR9-containing endosomes after BCR triggering can also increase BCR-initiated activation if foreign
DNA is recognized by TLR9 in the autophagosome (right). In this case, signaling through MAPK and NF-kB, which are downstream of both TLR9 and the
BCR, is increased.of the MAP kinase p38 and the c-Jun ter-
minal kinases (JNK), ultimately resulting
in expanded cellular proliferation and anti-
body secretion. Consequently, coligation
of BCR and TLR promotes antigen-spe-
cific B cell responses, illustrating how the
innate immune response can influence
and amplify adaptive immunity. In this
issue, Chaturvedi et al. (2008) provide
evidence for a novel mechanism for the in-
tegration of BCR-initiated signaling at the
plasma membrane with TLR9 signaling
from endosomes. The studies have impli-
cations for the understanding of both
enhanced host responses to pathogens
and potential processes that, when im-
properly regulated, can predispose the
host to inflammation and dangerous auto-
immunity.
Systemic autoimmunity has been tied to
defects in TLR signaling through genetic
evidence in humans and through targeted
mutations in mouse models of systemic
lupus erythematosus (SLE) (Christensen
and Shlomchik, 2007; Marshak-Rothstein
and Rifkin, 2007). Genetic studies of SLE
have identified risk alleles in TLR9 as well
as downstream TLR-signaling molecules.
SLE patients develop autoantibody re-
sponses to DNA- and RNA-associated
proteins (Yurasov et al., 2005), suggesting
that TLR7 and TLR9 signaling might be ab-
errantly deployed in order to overcome
normal B cell tolerance. Studies in mouse730 Immunity 28, June 2008 ª2008 Elseviermodels have shown that both TLR7 and
TLR9 signaling influence the development
of autoimmunity, although the underlying
mechanisms remain incompletely under-
stood. TLR9 ligation in B cells has been
implicated in class-switching and genera-
tion of autoantibodies against nucleo-
somes, and deletion of TLR9 in autoim-
mune-prone mouse strains decreases
anti-DNA antibody production. Interest-
ingly, TLR9 deletion also increases activa-
tion of plasmacytoid DCs (pDCs) and
exacerbates overall disease despite the
fact that it decreases autoantibody pro-
duction, demonstrating the complexity of
SLE disease pathogenesis (Christensen
et al., 2006).
The ability to bridge the innate and
adaptive immune systems by the linking
of specific antigen recognition and signal-
ing to the engagement of selective, but not
specific, innate immune receptors is in-
creasingly appreciated as an effective
strategy for response to evolutionarily con-
served and highly pathogenic organisms.
For the B cell, two paradigms have
emerged for explaining this adaptive and
innate receptor linkage at the molecular
level. In the first model, complement-
coated antigen engages BCR and coli-
gates the CD19 complex via bridging to
CD21 (Figure 1) (Dempsey et al., 1996).
CD19 crosslinking would serve to aug-
ment and expand BCR signaling andInc.therefore lower the threshold for the trig-
gering of B cell responsiveness. In the sec-
ond model, Gram-negative bacteria en-
gages both the BCR and TLR4 on the cell
surface, and the combined signaling deliv-
ered through these two receptors results in
increased levels of B cell activation and an-
tibody secretion and in decreased require-
ments for T cell help (Krieg et al., 1995).
Both models would enhance B cell activa-
tion by mechanisms that favor reactivity to
predictable pathogens and involve coliga-
tion of surface receptors, which would
seem to be a necessary requirement given
the link to BCR engagement. How, then,
can one explain the observed synergy be-
tween BCR and intracellularTLR receptors
such as TLR7 and TLR9?
Chaturvedi et al. (2008) reveal that the
mechanism by which BCR-TLR9 syner-
gism occurs is via the fusion of subcellular
organelles containing internalized anti-
gen-BCR complexes and TLR9 into auto-
phagosomes. They demonstrate that in-
duction of B cell activation through BCR
ligation causes mobilization of TLR9-con-
taining endosomes within 30 min of activa-
tion. Moreover, fusion of these TLR9-con-
taining vesicles into autophagosomes is
completely dependent on signals deliv-
ered through the BCR and is not depen-
dent on TLR signaling, given that it occurs
in the absence of CpG as well as in
Myd88/ B cells. Fusion is also
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rated by inhibition via PI3K inhibitors that
do not block BCR internalization. After an-
tigen-triggered BCR internalization, BCR-
antigen containing vesicles then specifi-
cally fuse with these TLR9-containing
autophagosomes, in which there is stable
sampling of antigen and presumably acti-
vation of TLR9 if unmethylated DNA is
present in the antigen cargo of the BCR.
It is in these intracellular vesicular bodies
that TLR9 and BCR signaling appears to
synergize and hyperactivate MAP-kinase
signaling.
The role of the autophagosome in the
synergistic activation of both BCR and
TLR9 signaling could be key in the inter-
action of the innate and adaptive immune
pathways and, as such, is under tight con-
trol. Phosphorylation of p38 occurs after
BCR or TLR9 activation, but confocal mi-
croscopy reveals that only BCR activation
triggers p38 phosphorylation within auto-
phagosomes. This observation in itself is
important and suggests that some signal-
ing through the BCR occurs from the re-
ceptor complex after internalization and
association with intracellular vesicles.
Upon internalization into phagosomes or
upon association with the ER-Golgi net-
work, the N-terminal signaling domains
of the BCR Iga-Igb are oriented toward
the cytosol, affording plausibility to this
concept. The ability of BCR to continue
signaling through the p38 MAPK pathway
as directly documented by the present
studies is provocative. If this is indeed
true, and provided that these signals are
biologically relevant, then it suggests an
additional dimension for BCR signaling
that will receive much more attention in
future studies.
The studies of Chaturvedi et al. (2008)
indicate that although recruitment ofTLR9-containing endosomes to these
autophagosomes enhances phosphoryla-
tion of p38, it is not required, because
phosphorylated p38 can be observed in
nonfused TLR9 endosomes in the ab-
sence of BCR signaling. Therefore, BCR
delivery of antigen to autophagosomes
allows TLR9 activation to be limited to
instances in which internalized antigen
contains unmethylated foreign DNA. Im-
portantly, internalized BCR is directed to
LAMP-1+ structures that contain MHC
class II antigen-presentation machinery,
allowing both enhanced signaling and
the induction of antigen presentation to
T cells. Inhibition of BCR internalization
alone or of internalization and early-sig-
naling events prevents TLR9-containing
endosome trafficking. This process is
specifically inhibited by a phospholipase
D (PLD) inhibitor, which does not prevent
BCR internalization or protein phosphory-
lation. This lipase is also required for
the trafficking of BCR into MHC class
II-containing endosomes, so this dual
role is fitting.
The identification of TLR-signaling
pathways by genetic-association studies
in lupus patients underscores the impor-
tance of these pathways in human auto-
immunity (Tao et al., 2007). TLR signaling
aids adaptive immunity in focusing on
a real threat from microbial pathogens;
when this threat is wrongly perceived,
autoimmunity could be the consequence.
Therefore, it is vital that we understand
how these pathways interact. For B cells,
this involves the limiting of TLR9 availabil-
ity to cases in which antigens can both li-
gate and signal through the BCR. Given
that most of the analysis by Chaturved
et al. (2008) is limited to the MAPK path-
way, it would be of interest to determine
whether increased or sustained p38Immphosphorylation is the dominant driver of
downstream effects on immunity and
whether other signaling pathways are
affected. If amplification of one pathway
is key, then a predisposition to B cell
hyperresponsiveness, loss of tolerance,
and disruption of normal checkpoints
leading to disease-associated autoimmu-
nity could result. Finally, the interest in the
use of TLR7-9 ligands for adjuvant
therapy has shown promise and might
represent a way of amplifying antibody
responses to protective antigens for
vaccine development. It will be critical for
this effort that we understand the traffick-
ing of antigens and TLR-containing endo-
somes so that the immune system’s pro-
tective strategies for the prevention of
autoimmunity are not overcome.
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